NCT00628433CompletedPhase 1
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Harbor Therapeutics0 sites27 target enrollmentStarted: February 2008Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 27
- Primary Endpoint
- safety and pharmacokinetics
Study Overview
Brief Summary
The purpose of this pilot, exploratory study is to evaluate the safety, tolerance, pharmacokinetics and potential activity of an investigational agent, HE3286, when administered orally, daily for 28 days to patients with mild-to-moderate ulcerative colitis.
Detailed Description
HE3286 has a potentially new mechanism of action that may improve the current therapeutic options available to patients with ulcerative colitis. In preclinical experiments, HE3286 has shown activity in animal models of ulcerative colitis. Additionally, HE3286 has shown to have anti-inflammatory activity associated with corticosteroids but without the side effects associated with corticosteroid use, such as immune suppression and bone loss.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18-65 years of age
- •Diagnosed (> 6 weeks) or recently relapsed active mild-to-moderate ulcerative colitis based on colonoscopy or flexible sigmoidoscopy
- •Mayo Scoring System for Assessment of Ulcerative Colitis Activity score of 4-9
- •Stable dose prior to screening of 6-mercaptopurine (50-150 mg/day 6-MP) [at least 2 months], Azathioprine (50-100 mg/day) [at least 2 months], and 5-ASA [at least 2 weeks]
- •For females of reproductive potential, agree to avoid pregnancy during the study and for 3 months following study completion, have a negative serum pregnancy test (b-HCG) at screening and negative urine pregnancy test and use an acceptable method of birth control
- •No history of narcotic and/or alcohol abuse within 2 years of screening and agrees to consume < 6 oz. of wine or equivalent per day
- •No experienced renal or liver disease by history and/or based on laboratory results
- •Must provide voluntary, written, informed consent prior to screening evaluations and be able to follow verbal and written instructions
- •Must be able to swallow capsules
Exclusion Criteria
- •Primary sclerosing cholangitis
- •Positive for C. difficile toxin in the stool
- •Requires hospitalization for treatment of severe ulcerative colitis
- •History of clinically significant cardiovascular disease (including coronary artery disease), clinically significant hepatic, respiratory or renal abnormalities, or clinically significant endocrine disorders (not including diabetes)
- •Clinically significant abnormalities on laboratory results (renal insufficiency, liver function abnormalities, abnormal WBC or ANC)
- •Any clinically significant unstable medical abnormality, chronic disease, or active, serious clinical infection or condition, other than ulcerative colitis
- •Uncontrolled hypertension defined as systolic BP > 160 mmHg and/or diastolic BP > 100 mmHg on three or more assessment on more than one day(blood pressure must be stable for > 3 months prior to screening)
- •Malignancy within the past 5 years, except for successfully treated basal cell carcinoma of the skin
- •Requiring or receiving anti-TNF-a or other immune modulating drugs (other than 6-MP or azathioprine) within 8 weeks prior to screening
- •Requiring or receiving any of the following within 4 weeks of the screening visit: interleukins, steroids (i.e., anabolic steroids, glucocorticoids), narcotics, anti-cancer chemotherapeutic agents, metabolic inhibitors or nutraceuticals with immune enhancement claims
- •Requiring oral or intravenous cortisone
- •Requiring corticosteroid enemas
- •Acute illness within 10 days prior to Day 1 or taking antibiotics for UC (but not for a infectious disease) within 14 days of Day 1
- •Any clinical condition or receiving therapy that, in the opinion of the Investigator, would make the patient unsuitable for study or unable to comply with the dosing requirements
Arms & Interventions
1
Placebo Comparator
Placebo
Intervention: Placebo (Drug)
2
Experimental
HE3286 5 mg daily
Intervention: HE3286 (Drug)
3
Experimental
HE3286 10 mg daily
Intervention: HE3286 (Drug)
4
Experimental
HE3286 20 mg daily
Intervention: HE3286 (Drug)
5
Experimental
HE3286 4 mg daily
Intervention: HE3286 (Drug)
Outcomes
Primary Outcomes
safety and pharmacokinetics
Time Frame: duration of the study
Secondary Outcomes
- assess activity on the signs and symptoms of active mild-to-moderate ulcerative colitis(duration of the study)
Investigators
Similar Trials
Completed
Phase 1
A Phase 1 Dose Escalation Study of VX-973 in Healthy ParticipantsPainNCT06615570Vertex Pharmaceuticals Incorporated30
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy VolunteersHealthyNCT02480296MyoKardia, Inc.60
Completed
Phase 1
A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy VolunteersTTR-mediated AmyloidosisNCT01814839Alnylam Pharmaceuticals85
Completed
Phase 1
A Phase 1 Dose Escalation Study of VX-973 in Healthy AdultsPainNCT05866055Vertex Pharmaceuticals Incorporated30
Completed
Phase 1
A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy ParticipantsAcute PainNCT05347394Vertex Pharmaceuticals Incorporated100